Abott Short OpportunityAbott did the last push upside and took the remaining liquidity, I m waiting the price to go back to 110 before taking a short entry
ABL trade ideas
Abbott Laboratories Shows Resilience with Strong Q1 Performance In the dynamic landscape of healthcare, Abbott Laboratories (NYSE: NYSE:ABT ) stands out with its robust first-quarter performance, showcasing resilience and adaptability amidst challenging conditions. Bolstered by a surge in medical device sales and buoyed by promising growth across multiple sectors, Abbott has exceeded expectations and raised its annual guidance, signaling confidence in its trajectory. Let's delve deeper into the factors driving Abbott's success and the implications for investors.
1. Medical Devices Lead the Charge: Abbott's ( NYSE:ABT ) first-quarter success story is largely attributed to the stellar performance of its Medical Devices segment, which witnessed a remarkable organic growth of 14.3%. The star performer within this segment was FreeStyle Libre, demonstrating a phenomenal 23.3% organic growth, underscoring the growing demand for innovative healthcare solutions.
2. Diversification Pays Off: Abbott's diversified portfolio, spanning Established Pharmaceuticals, Nutrition, and Diagnostics, was pivotal in driving overall growth. With double-digit organic growth in Established Pharmaceuticals and substantial gains in Nutrition and Diagnostics, Abbott has showcased its ability to capture opportunities across various healthcare segments.
3. Strategic Innovations: The approval of Abbott's Heart Valve Repair Device by the FDA marks a significant milestone, reinforcing the company's commitment to advancing medical technology. This breakthrough underscores Abbott's relentless pursuit of innovation to address critical healthcare needs, thereby positioning the company for sustained growth and market leadership.
4. Earnings Beat and Guidance Revision: Abbott's impressive adjusted diluted earnings per share of $0.98 not only surpassed analyst estimates but also instilled confidence in the company's financial performance. The upward revision of its fiscal year 2024 adjusted EPS guidance to $4.55-$4.70 reflects management's bullish outlook and underscores Abbott's strong growth prospects in the coming quarters.
5. Market Response and Outlook: Despite the premarket dip in NYSE:ABT shares, Abbott's robust performance and revised guidance signal a compelling investment opportunity. With a solid foundation, innovative pipeline, and optimistic outlook, Abbott is poised to navigate uncertainties and deliver sustainable value to shareholders in the long term.
Investment Opportunity on Abbott Laboratories (Short)Wyckoff in place on ABT, I'm expecting the price reaching my supply zone in grey by doing an UTAD (second liquidation) and the continue the bearish trend.
Upside risk (5.23%)
Downside profit (50%)
ABT breakout!ABT just broke out of a downtrend while simultaneously battling a key resistance zone. It did so, while gaining positive momentum within a monthly TTM squeeze (and firing the Daily Squeeze). If it can hold above the newly formed support, it might be ready for a bullish run up to its previous all-time-high, which is coincidentally equidistant from the newly formed low. Before it can do that, it needs to fight through resistance within the "golden" fibonacci zone (up to $122). I'll wait for it to break free of this zone before I try to ride it up to the next level and/or the high!
Long-term position in Abbott Laboratories $ABTThis week, I entered into a long-term position in Abbott Laboratories NYSE:ABT
Timeframe: M
SL: ~$98.59
Target: ~$155
Short term ABT bearishNYSE:ABT Has formed a bearish impulse with a healthy correction and a lower degree impulse with a lower degree correction that is breaking out of the larger degree trend line!
This is great confirmation of a trend continuation setup.
Since the retracement is deep though, 78.6%, the trend continuation impulse could be short lived and reverse, or continue down side.
Abbott Laboratories (ABT) Navigating Earnings
Abbott Laboratories ( NYSE:ABT ) recently reported earnings that slightly missed expectations at the midpoint, causing a 3.3% dip in NYSE:ABT stock to $110.21. However, a closer look at the results reveals a more nuanced story. Despite the earnings guidance falling short by three pennies at $4.60 per share for the year, the health care giant remains resilient, projecting a robust 8% to 10% organic sales growth. Investors should pay attention as NYSE:ABT stock forms a saucer base with a potential buy point at $115.83.
Strong Growth in Medical Devices:
One of the key drivers behind Abbott's solid performance was the outstanding growth in its medical devices segment. Sales in this category surged 15.4% organically to $4.44 billion. Notably, the diabetes division played a significant role, with revenues reaching $1.55 billion, marking a substantial 20.7% increase. The star performer in this space was Abbott's body-worn glucose monitor, FreeStyle Libre, which contributed $1.4 billion in sales, up by an impressive 23.8% on an organic basis.
Electrophysiology Segment Shines:
Another highlight for Abbott ( NYSE:ABT ) was the electrophysiology segment, where revenue grew 15.9% organically to nearly $2.2 billion. This growth is particularly noteworthy considering the challenges posed by a new technology called pulsed field ablation (PFA), which is emerging in the electrophysiology testing space. Analysts believe that Abbott's robust performance in this segment allays fears of losing market share to PFA, underscoring the company's adaptability and resilience.
Rapid Diagnostics Faces Headwinds:
While Abbott ( NYSE:ABT ) celebrated success in medical devices and electrophysiology, the rapid diagnostics segment faced headwinds. Excluding Covid tests, sales declined by 13.7% to $862 million. The decline was attributed to a later-than-expected flu season, with cases spiking in January. Despite this setback, core lab sales managed to climb 9.7% to $1.37 billion, showcasing the diversified portfolio and the ability to navigate challenges.
Conclusion:
Abbott Laboratories' ( NYSE:ABT ) recent earnings report might have initially disappointed investors, but a deeper analysis reveals a company that is strategically positioned for growth. With a saucer base forming and a potential buy point at $115.83, savvy investors may see this dip in NYSE:ABT stock as a buying opportunity. Abbott's ability to innovate in the medical devices space, navigate challenges in rapid diagnostics, and shine in electrophysiology suggests that the company is well-poised for sustained success in the dynamic healthcare industry.
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t sold the regional top on ABT:
Nor reentered this fantastic dip:
Then analyzing the options chain and the chart patterns of ABT Abbott Laboratories prior to the earnings report this week,
I would consider purchasing the 115usd strike price at the money Calls with
an expiration date of 2024-2-16,
for a premium of approximately $2.26.
The chart is overextended and the RSI overbought, but I think there is one more leg to go before a correction.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Abbott laboratories at its Breakout Zone Abbott laboratories at its Break out Zone anday See 20% upside in coming week
ABT - Minor High ShortTitle Minor High Sell
Trade Theme Daily
Sector/Stock ABT
Trend R/R
Propulsion No
Vscore Yes
Vprofile Yes
RAF 50%
Darvas Weekly
Darvas 3.0 Yes
Entry 95.09
Profit/Breakeven 93.55
Stop Loss 15%
Option Option Play
ABT ShortM15, M30, and H1 are overbought, and there is a pattern for M15 to sell. This trade is with the H4 and Daily trend so it should go all the way to the bottom. There are many signs to sell this trade, and there is very good resistance at this level, stop loss above 100 should be good.
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t bought ABT here:
or sold it here:
Then analyzing the options chain and the chart patterns of ABT Abbott Laboratories prior to the earnings report this week,
I would consider purchasing the 91usd strike price Calls with
an expiration date of 2023-10-27,
for a premium of approximately $3.15.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
Abott to turnaround at trend line support?Abbott Laboratories - 30d expiry - We look to Buy at 104.11 (stop at 100.91)
The trend of higher lows is located at 104.
The primary trend remains bullish.
This stock has seen good sales growth.
104 continues to hold back the bears.
Although the bears are in control, the stalling negative momentum indicates a turnaround is possible.
Our profit targets will be 112.11 and 114.11
Resistance: 106.20 / 108.50 / 110.00
Support: 103.28 / 100.38 / 99.30
Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group
Excellent Risk Reward in ABT @103-105ABT is trading at a fantastic level and is in an uptrend on the long-term chart. We can construct a position in this company with a risk-reward ratio of 1:1 or 1:2. At this point, it appears to be pretty nice.
ABT - 9 months SYMMETRICAL TRIANGLE══════════════════════════════
Since 2014, my markets approach is to spot
trading opportunities based solely on the
development of
CLASSICAL CHART PATTERNS
🤝Let’s learn and grow together 🤝
══════════════════════════════
Hello Traders ✌
After a careful consideration I came to the conclusion that:
- it is crucial to be quick in alerting you with all the opportunities I spot and often I don't post a good pattern because I don't have the opportunity to write down a proper didactical comment;
- since my parameters to identify a Classical Pattern and its scenario are very well defined, many of my comments were and would be redundant;
- the information that I think is important is very simple and can easily be understood just by looking at charts;
For these reasons and hoping to give you a better help, I decided to write comments only when something very specific or interesting shows up, otherwise all the information is shown on the chart.
Thank you all for your support
🔎🔎🔎 ALWAYS REMEMBER
"A pattern IS NOT a Pattern until the breakout is completed. Before that moment it is just a bunch of colorful candlesticks on a chart of your watchlist"
═════════════════════════════
⚠ DISCLAIMER ⚠
The content is The Art Of Charting's personal opinion and it is posted purely for educational purpose and therefore it must not be taken as a direct or indirect investing recommendations or advices. Any action taken upon these information is at your own risk.
$ABT with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for NYSE:ABT after a positive under reaction following its earnings release placing the stock in drift A with an expected accuracy of 85.71%.
Abbott triggered by positive earnings Abbott Laboratories Second-Quarter Results Beat Expectations Despite Lower COVID-19 Testing Sales
The company now anticipates about $1.3 billion in sales from COVID-19 testing products for 2023, compared with the prior forecast of $1.5 billion, "due to current testing dynamics, including lower demand for testing following the end of the public health emergency in May," Chief Financial Officer Robert Funck said on the call.
For the third quarter, Abbott anticipates adjusted earnings of roughly $1.10 per share, according to Funck. Analysts estimate EPS of $1.11.
Technicals:
Cycle Sniper Reversal Filter Headed Nort
Cycle Sniper Bullish ddeviation
Key Resistance: 116 $
Closing above 116 $
Targets: 122 $ and 128 $
Abbott Laboratories in a bull flag.Abbott Labratories - 30d expiry - We look to Buy a break of 109.51 (stop at 106.31)
The primary trend remains bullish.
This stock has seen good sales growth.
Expect trading to remain mixed and volatile.
109.34 has been pivotal.
Posted a bullish Flag formation.
A break of 109.34 is needed to confirm the outlook.
The bias is to break to the upside.
Our profit targets will be 117.51 and 119.51
Resistance: 108.50 / 109.34 / 112.95
Support: 106.80 / 105.96 / 104.00
Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group.
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t bought ABT here:
Then analyzing the options chain of ABT Abbott Laboratories prior to the earnings report this week,
I would consider purchasing the 108usd strike price in the money Puts with
an expiration date of 7/21/2023,
for a premium of approximately $2.55.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
Bullish sentiment on ABTI like the double bottom ABT just completed. RSI is trending up. The pullback over the last week was on decreasing volume. Looking for a leg up from here.
#ABT Straddle! Notional value - 1.6M$Based on our team's research of the options market, we expect buy activity at the support level or sell activity at the resistance.
We do research and find new opportunities every day.
Please feel free to leave any comments you have and like this idea if you agree with us. Any feedback or comments will be read. We appreciate it all.
